AGENDA AGENDA KRATOM SYMPOSIUM
February, 17th: Day 1
OPENING DAY 5:00 PM - 7:00 PM
4:30-7:15PM
5:00-7:00
8:00-8:40
8:40-9:10
9:10-9:30
9:30-9:50
9:50-10:10
10:10-10:30
February, 18th: Day 2
8:00 AM - 7:30 PM
7:45-9:30AM
Shuttle Loop
Courtyard/Residence Inn, SpringHill Suites & UF Research and Academic Center
10:30-11:00
Breakfast
Welcome & Conference Opening
Design, synthesis, characterization and biological evaluation of some Kratom derived analogs as potential anti-cancer agents
Preet Mohinder Singh Bedi, Guru Nanak Dev University, India
The impact of prenatal exposure to kratom (mitragynine) on the developmental outcomes of offspring
Farah Wahida Suhaimi, Centre for Drug Research, Universiti Sains Malaysia, Malaysia
Mitragynine-Induced Reinstatement of MorphineSeeking Behavior in a Rat Model of Relapse
Norsyifa Harun, Centre for Drug Research, Universiti Sains Malaysia, Malaysia
From Leaf to Lab: The Challenges of Kratom-related Deaths
Justin Brower, NMS Labs, USA
Coffee Break
February, 18th: Day 2
11:00-11:20
Assessing the Analgesic Efficacy of Encapsulated Kratom in Altering Sensory Thresholds in Dogs, using Electric, Thermal, and Mechanical Quantitative Sensory Testing (QST)
Elizabeth A. Maxwell, University of Florida, USA
11:20-11:40
11:40-12:00
Kratom’s Major Alkaloids: Analgesic Potency and Impact on Hippocampal Synaptic Plasticity
Zurina Hassan, Centre for Drug Research, Universiti Sains Malaysia, Malaysia
Dissecting the Neurobehavioral and Circuit-Level Mechanisms of Kratom Alkaloids Using Zebrafish
Satoshi Ogawa, Monash University, Malaysia
12:00-12:20 12:20-1:30
Toxicological Evaluation of Naturally Derived Kratom Extracts in Humans and Rodents
Sibyl Swift, Johnson Foods, Canada
Lunch & Networking
1:30-1:40
1:40-1:50
1:50-2:00
2:00-2:10
February, 18th: Day 2
Transport of mitragynine across the blood-brain barrier: evidence for organic anion transporter involvement and P-glycoprotein restriction
Juzaili Azizi, Centre for Drug Research, Universiti Sains Malaysia, Malaysia
Biased µ-Opioid Receptor Signaling of Isolated Kratom Alkaloids in a BRET Assay
Martin Kuchař, UCT Prague, Prague, Czech Republic
Mixtures Biotransformation: Multi-Layer Molecular Networking of Kratom Liver Metabolites
William J. Crandall, Emory University, USA
Therapeutic Potential of Kratom (Mitragyna speciosa) Extract in Attenuating Motor Deficits and Modulating Neural Oscillations in Multiple Mouse Models of Parkinson's Disease
Dania Cheaha, Prince of Songkla University, Thailand
February, 18th: Day 2 CONTINUED
2:10-2:20
Effect of encapsulated kratom on naturally occurring osteoarthritic pain in a canine model, a prospective, randomized, crossover, double-blinded, placebocontrolled clinical trial
Elizabeth A. Maxwell, University of Florida, USA
2:20-2:30
2:40-2:50
Biotransformation of mitragynine by kratomassociated endophytic fungi
Juraithip Wungsintaweekul, Prince of Songkla University, Thailand
Selected Kratom Alkaloids as Multifunctional Cognitive Enhancers in Treating Alzheimer’s Disease via Inhibition of Cholinesterase and β-Amyloid1-42
Aggregation
2:30-2:40 Coffee Break
Nelson Jeng-Yeou Chear, Centre for Drug Research, Universiti Sains Malaysia, Malaysia
Metabolomic analysis of blood plasma from kratom and non-kratom users using an NMR-based approach
Boon Keat Khor, Centre for Drug Research, Universiti Sains Malaysia, Malaysia
2:50-3:00
3:00-3:20
3:20-3:40
3:40-4:00 4:00-4:20
February, 18th: Day 2
Translational Safety Evaluation of Mitragynine in Rats: An Integrated Pharmacokinetic–Pharmacodynamic Approach
Manoj Gundeti, University of Florida, USA
Comparative lethality of kratom leaf powder, kratom leaf extract, 7-hydroxymitragynine powder, and a 7hydroxymitragynine commercial product
Erin Berthold, Planted in Science Consulting LLC, USA
Non-Alkaloid Constituents of Mitragyna speciosa
Leaves as Novel Antidiabetic Agents: In Vitro to In Vivo Antidiabetic and Wound Healing Studies In Vivo Evaluation of the Dual Anti-Inflammatory Potential of Kratom Alkaloid Extract
Masteria Yunovilsa Putra, National Research and Innovation Agency (BRIN), Indonesia
Dwi Wahyu Indriani, National Research and Innovation Agency (BRIN), Indonesia
February, 18th: Day 2
4:20-4:40
Kratom (Mitragyna speciosa Korth.) alkaloids
nanobilosomal formulation enhanced cytotoxic activities in cancer cells: an in vitro study
A’liyatur Rosyidah, National Research and Innovation Agency (BRIN), Indonesia
4:40-5:00
5:00-5:20
5:30-7:30
6:30-7:45PM
From Genes to Alkaloids: Unraveling Mitragyna Genetics for Drug Discovery
Satya Swathi Nadakuduti, University of Florida
Assessments of accumbal local field potential signals during expression, extinction, and reinstatement in methamphetamine addiction-related mice following treatment with kratom alkaloid extract
Jakkrit Nukitram, Khoen Kaen University, Thailand
Reception with Food
Courtyard/Residence Inn, SpringHill Suites & UF Research and Academic Center Shuttle Loop
8:00-9:00
9:00-10:00
10:00-10:20
10:20-10:40
10:40-11:00
11:00-11:20
February, 19th: Day 3
8:00 AM - 5:40 PM
7:45-9:30AM
Breakfast
11:20-11:40
Courtyard/Residence Inn, SpringHill Suites & UF Research and Academic Center Shuttle Loop
Keynote Address: Nora Volkow utes of Health
Effects of Botanical Stress-Relief Formulation
combining Kava (Piper methysticum) and Kratom (Mitragyna speciosa): A Real-World Observational Study
Paloma Lehfeldt, British Columbia Institute of Technology, Canada
Differential Effects of Kratom (Mitragyna speciosa)
Treatment on Frontotemporal EEG Asymmetry in Methamphetamine and Opioid Use Disorders
Nifareeda Samerphob, Prince of Songkla University, Thailand
Mitragynine as a Potential Therapeutic for Methamphetamine Use Disorder without Impacting Food-Motivated Behavior
Jenny Wilkerson, Texas Tech University Health Sciences Center, USA
Dose-Dependent Effects of a Mitragyna speciosa (Korth.) formulation on Focus and Energy: A Real-World Observational Study
Michael Chan, British Columbia Institute of Technology, Canada
Coffee Break
February, 19th: Day 3
11:40-11:55
Kratom Before Bed: Sleep Aid or Sleep Disruptor?
Chung Jung Mun, Arizona State University, USA
11:55-12:10
12:10-12:25
7-hydroxymitragynine toxicity: a case report and the imperative for dynamic poison center surveillance and clinical toxicology analysis
12:25-1:20
Mallory Pullman, Mississippi Poison Control, University of Mississippi Medical Center, USA
Understanding Kratom’s Effects and Abuse Potential: Design of the First FDA-Funded Human Study
Christopher Verrico, Baylor College of Medicine, USA
Lunch & Networking
1:20-1:40
1:40-2:00
2:00-2:20
2:20-2:40
February, 19th: Day 3
Statewide analysis reveals 965 cases of MitragynineAssociated Drug Intoxication
Armiel Suriaga, Florida Atlantic University, USA
A Pilot Study on Kratom Use Among Children and Adolescents in the Czech Republic: Perspectives from Outpatient Addiction Services
Tomas Jandac, Charles University, Prague, Czechia
Distinctive Use Patterns and DSM-5 criteria of kratom and semi-synthetic derivative products: results from an online survey and product analysis
Oliver Grundmann, University of Florida, USA
The Online Semi-Synthetic Kratom Market in Czech Republic’s Grey Zone: A Web-Based Surveillance Study
Neshalatha Govarthnapany, Charles University, Prague, Czechia
2:40-3:10
Coffee Break
February, 19th: Day 3
3:10-3:30
A double-blind, randomized, placebo-controlled study to evaluate the safety and tolerability of kratom product formulations and their relative effects on exercise-induced muscle soreness in healthy adult participants
Jenelle Patterson, Gowling WLG, Canada
3:30-3:50
3:50-4:10
Perceived Benefits, Risks, and Healthcare Interactions Among People Who Use Kratom: A Qualitative Inquiry
Patty Timmons, Arizona State University, USA
Kratom and mitragynine as a treatment of alcohol use disorder and its comorbidities
Christian P. Müller, Friedrich-Alexander-University of ErlangenNürnberg, Germany
4:10-4:30
Mitragynine and 7-hydroxymitragynine plasma pharmacokinetics in healthy human participants after controlled oral kratom extract administration and comparison to pharmacokinetics following controlled oral dried kratom leaf powder
Marilyn A. Huestis, Thomas Jefferson University, USA
February, 19th: Day 3
4:30-4:50 4:50-5:10
Evaluation of a Commercial Kratom Urine Test: Inability to Detect 7-Hydroxymitragynine and Cross-Reactivity With Kratom Compounds -
Roman A. Mirra
From Plant-Based to Lab-Made: Kratom, Synthetic Opioids, and MGM 15
Abhisheak Sharma, University of Florida, USA
5:10-5:30
5:30 5:30-6:30PM
Metabolomics guided investigation of 7hydroxymitragynine products reveals novel alkaloids not found in kratom leaves
Ryland T. Giebelhaus, University of Victoria, Canada
End of Day 3
Courtyard/Residence Inn, SpringHill Suites & UF Research and Academic Center Shuttle Loop
February, 20th: Day 4
8:00 AM - 3:00 PM
7:45-9:30AM
Shuttle Loop
8:00-9:00
Courtyard/Residence Inn, SpringHill Suites & UF Research and Academic Center
Breakfast
9:00-9:20 Propagation Methods Alter the Alkaloid Profiles in Kratom
Narumon Sengnon, Prince of Songkla University, Thailand
9:20-9:40 9:40-10:00 10:00-10:30
The Evolution of Kratom and 7-Hydroxymitragynine Research: A Quantitative Network Approach
Alessandro Carollo, University of Trento, Italy
Kratom in a College Town: Availability, Cost, and Composition Analysis
Avery Michienzi, University of Virginia, USA
Coffee Break
February, 20th: Day 4
10:30-10:50
10:50-11:10
Kratom Legalization and Its Consequences in Thailand: Evidence, Policy Implications, and Global Lessons
Muhammadfahmee Talek, Prince of Songkla University, Thailand
Current Regulatory Landscape of Kratom and KratomDerived Products
Robert Durkin, AWG Law, USA
11:10-11:30
11:30-11:50
When Scientific Evidence and Data Collide with Public Policy - How Evidence and Data Must Prevail Over Opinions
Mac Haddow, American Kratom Association, USA
Mapping the Czech Online Market Before the Implementation of the Psychomodulatory Substances Act,
Roman Gabhrelik, Charles University, Czechia
11:50-1:00
1:00-3:00
2:30-3:30PM
Lunch & Networking
Town Hall - Moderator: Stephen Cutler
KRATOM SYMPOSIUM SCIENTIFIC 5th
W E H O P E T O S E E Y O U N E X T T I M E !